Iptakalim: A potential antipsychotic drug with novel mechanisms?

European Journal of Pharmacology

Volumn 634, Issue 1-3, 2010, Pages 68-76

  Sun, Tao ^a,b   Zhao, Changjiu ^b   Hu, Gang ^a   Li, Ming ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Amphetamine; Antipsychotic drug; C Fos; Conditioned avoidance response; Iptakalim; KATP channel; Phencyclidine; Prepulse inhibition

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM); AMPHETAMINE; CLOZAPINE; FLUOXETINE; HALOPERIDOL; IPTAKALIM; PHENCYCLIDINE; PROTEIN C FOS; RISPERIDONE; N-(1-METHYLETHYL)-1,1,2-TRIMETHYLPROPYLAMINE; NEUROLEPTIC AGENT; PROPYLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPSYCHOTIC ACTIVITY; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; GENE EXPRESSION; HYPERACTIVITY; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SEPTUM NUCLEUS; ANIMAL; AVOIDANCE BEHAVIOR; BRAIN; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECTS; HYPERKINESIS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; SCHIZOPHRENIA; SENSORY GATING; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BRAIN; CELL MEMBRANE; HYPERKINESIS; MALE; PROPYLAMINES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; SENSORY GATING;

EID: 77951206390     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.02.024     Document Type: Article

References (54)

1. Abekawa T., Ito K., Koyama T. Different effects of a single and repeated administration of clozapine on phencyclidine-induced hyperlocomotion and glutamate releases in the rat medial prefrontal cortex at short- and long-term withdrawal from this antipsychotic. Naunyn Schmiedebergs Arch. Pharmacol. 2007, 375:261-271.
2. Akhondzadeh S., Mojtahedzadeh V., Mirsepassi G.R., Moin M., Amini-Nooshabadi H., Kamalipour A. Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia. J. Clin. Pharm. Ther. 2002, 27:453-459.
3. Allen J.W., Etcheberrigaray R. Potassium channels in neuropsychiatric disorders: potential for pharmacological intervention. CNS Drugs 1998, 10:61-82.
4. Andersen M.P., Pouzet B. Effects of acute versus chronic treatment with typical or atypical antipsychotics on d-amphetamine-induced sensorimotor gating deficits in rats. Psychopharmacology (Berl) 2001, 156:291-304.
5. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol. Toxicol. (Copenh) 1982, 51:321-329.
6. Arnt J. Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of d-amphetamine. Eur. J. Pharmacol. 1995, 283:55-62.
7. Belujon P., Grace A.A. Critical role of the prefrontal cortex in the regulation of hippocampus-accumbens information flow. J. Neurosci. 2008, 28:9797-9805.
8. Bowyer J.F., Spuhler K.P., Weiner N. Effects of phencyclidine, amphetamine and related compounds on dopamine release from and uptake into striatal synaptosomes. J. Pharmacol. Exp. Ther. 1984, 229:671-680.
9. Carpenter W.T., Koenig J.I. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 2008, 33:2061-2079.
10. Culm K.E., Hammer R.P. Recovery of sensorimotor gating without G protein adaptation after repeated D2-like dopamine receptor agonist treatment in rats. J. Pharmacol. Exp. Ther. 2004, 308:487-494.
11. Dick G.M., Sanders K.M. (Xeno)estrogen sensitivity of smooth muscle BK channels conferred by the regulatory beta1 subunit: a study of beta1 knockout mice. J. Biol. Chem. 2001, 276:44835-44840.
12. Dunn-Meynell A.A., Rawson N.E., Levin B.E. Distribution and phenotype of neurons containing the ATP-sensitive K+ channel in rat brain. Brain Res. 1998, 814:41-54.
13. Feifel D., Reza T., Robeck S. Antipsychotic potential of CCK-based treatments: an assessment using the prepulse inhibition model of psychosis. Neuropsychopharmacology 1999, 20:141-149.
14. Freedman J.E., Lin Y.J. ATP-sensitive potassium channels: diverse functions in the central nervous system. Neuroscientist 1996, 2:145-152.
15. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001, 156:117-154.
16. Hertel P., Mathe J.M., Nomikos G.G., Iurlo M., Mathe A.A., Svensson T.H. Effects of d-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behav. Brain Res. 1995, 72:103-114.
17. Hu J., Lindenberger K., Hu G., Wang H., Lukas R.J., Wu J. Iptakalim as a human nicotinic acetylcholine receptor antagonist. J. Pharmacol. Exp. Ther. 2006, 316:914-925.
18. Kulkarni J., Riedel A., de Castella A.R., Fitzgerald P.B., Rolfe T.J., Taffe J., Burger H. Estrogen-a potential treatment for schizophrenia. Schizophr. Res. 2001, 48:137-144.
19. Li M., Fletcher P.J., Kapur S. Time course of the antipsychotic effect and the underlying behavioral mechanisms. Neuropsychopharmacology 2007, 32:263-272.
20. Li M., He W., Mead A. An investigation of the behavioral mechanisms of antipsychotic action using a drug-drug conditioning paradigm. Behav. Pharmacol. 2009, 20:184-194.
21. Li M., He W., Mead A. Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus. Behav. Pharmacol. 2009, 20:84-98.
22. Lin Y.J., Greif G.J., Freedman J.E. Multiple sulfonylurea-sensitive potassium channels: a novel subtype modulated by dopamine. Mol. Pharmacol. 1993, 44:907-910.
23. Miki T., Seino S. Roles of KATP channels as metabolic sensors in acute metabolic changes. J. Mol. Cell. Cardiol. 2005, 38:917-925.
24. Millan M.J., Brocco M., Gobert A., Joly F., Bervoets K., Rivet J., Newman-Tancredi A., Audinot V., Maurel S. Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat. Eur. J. NeuroSci. 1999, 11:4419-4432.
25. Millan M.J., Loiseau F., Dekeyne A., Gobert A., Flik G., Cremers T.I., Rivet J.M., Sicard D., Billiras R., Brocco M. S33138 (N-[4-[2-[(3aS, 9bR)-8-cyano-1, 3a, 4, 9b-tetrahydro[1] benzopyrano[3, 4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects. J. Pharmacol. Exp. Ther. 2008, 324:1212-1226.
26. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005, 10:79-104.
27. Mo Y.Q., Jin X.L., Chen Y.T., Jin G.Z., Shi W.X. Effects of l-stepholidine on forebrain Fos expression: comparison with clozapine and haloperidol. Neuropsychopharmacology 2005, 30:261-267.
28. Moghaddam B., Homayoun H. Divergent plasticity of prefrontal cortex networks. Neuropsychopharmacology 2008, 33:42-55.
29. Natesan S., Reckless G.E., Nobrega J.N., Fletcher P.J., Kapur S. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 2006, 31:1854-1863.
30. Paxinos G., Watson C. The rat brain in stereotaxic coordinates, sixth ed 2007, Academic Press, New York.
31. Robertson G.S., Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 1992, 46:315-328.
32. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Pharmacol. Exp. Ther. 1994, 271:1058-1066.
33. Ross C.A., Margolis R.L., Reading S.A., Pletnikov M., Coyle J.T. Neurobiology of schizophrenia. Neuron 2006, 52:139-153.
34. Sotty F., Damgaard T., Montezinho L.P., Mork A., Olsen C.K., Bundgaard C., Husum H. Antipsychotic-like effect of retigabine, a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission. J. Pharmacol. Exp. Ther. 2008.
35. Sun T., Hu G., Li M. Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs. Eur. J. Pharmacol. 2009, 602:334-342.
36. Swanson C.J., Schoepp D.D. A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists. Ann. N. Y. Acad. Sci. 2003, 1003:309-317.
37. Swerdlow N.R., Bakshi V., Geyer M.A. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J. Pharmacol. Exp. Ther. 1996, 279:1290-1299.
38. Swerdlow N.R., Geyer M.A., Braff D.L. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 2001, 156:194-215.
39. Swerdlow N.R., Weber M., Qu Y., Light G.A., Braff D.L. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl) 2008, 199:331-388.
40. Thomzig A., Laube G., Pruss H., Veh R.W. Pore-forming subunits of K-ATP channels, Kir6.1 and Kir6.2, display prominent differences in regional and cellular distribution in the rat brain. J. Comp. Neurol. 2005, 484:313-330.
41. Valenstein E.S. Blaming the Brain: The Truth About Drugs and Mental Health 1998, xi. Free Press, New York, 292pp.
42. Wadenberg M.L., Hicks P.B. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?. Neurosci. Biobehav. Rev. 1999, 23:851-862.
43. Wang H., Zhang Y.L., Tang X.C., Feng H.S., Hu G. Targeting ischemic stroke with a novel opener of ATP-sensitive potassium channels in the brain. Mol. Pharmacol. 2004, 66:1160-1168.
44. Wang H., Long C.L., Zhang Y.L. A new ATP-sensitive potassium channel opener reduces blood pressure and reverses cardiovascular remodeling in experimental hypertension. J. Pharmacol. Exp. Ther. 2005, 312:1326-1333.
45. Wang H., Zhang Y.L., Chen Y.P. Targeting small arteries of hypertensive status with novel ATP-sensitive potassium channel openers. Curr. Vasc. Pharmacol. 2005, 3:119-124.
46. Wang S., Hu L.F., Yang Y., Ding J.H., Hu G. Studies of ATP-sensitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson's disease: implications for treating Parkinson's disease?. Neuropharmacology 2005, 48:984-992.
47. Wang S., Hu L.F., Zhang Y., Sun T., Sun Y.H., Liu S.Y., Ding J.H., Wu J., Hu G. Effects of systemic administration of iptakalim on extracellular neurotransmitter levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats. Neuropsychopharmacology 2006, 31:933-940.
48. Yang J., Hu L.F., Liu X., Zhou F., Ding J.H., Hu G. Effects of iptakalim on extracellular glutamate and dopamine levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Life Sci. 2006, 78:1940-1944.
49. Yang Y.J., Wang Q.M., Hu L.F., Sun X.L., Ding J.H., Hu G. Iptakalim alleviated the increase of extracellular dopamine and glutamate induced by 1-methyl-4-phenylpyridinium ion in rat striatum. Neurosci. Lett. 2006, 404:187-190.
50. Yang Y.J., Zhang S., Ding J.H., Zhou F., Hu G. Iptakalim protects against MPP+-induced degeneration of dopaminergic neurons in association with astrocyte activation. Int. J. Neuropsychopharmacol. 2008, 1-11.
51. Zhang S., Zhou F., Ding J.H., Zhou X.Q., Sun X.L., Hu G. ATP-sensitive potassium channel opener iptakalim protects against MPP-induced astrocytic apoptosis via mitochondria and mitogen-activated protein kinase signal pathways. J. Neurochem. 2007, 103:569-579.
52. Zhao C., Li M. C-Fos identification of neuroanatomical sites associated with haloperidol and clozapine disruption of maternal behavior in the rat. Neuroscience 2010, 166:1043-1055.
53. Zhou F., Wu J.Y., Sun X.L., Yao H.H., Ding J.H., Hu G. Iptakalim alleviates rotenone-induced degeneration of dopaminergic neurons through inhibiting microglia-mediated neuroinflammation. Neuropsychopharmacology 2007, 32:2570-2580.
54. Zweifel L.S., Parker J.G., Lobb C.J., Rainwater A., Wall V.Z., Fadok J.P., Darvas M., Kim M.J., Mizumori S.J., Paladini C.A., Phillips P.E., Palmiter R.D. Disruption of NMDAR-dependent burst firing by dopamine neurons provides selective assessment of phasic dopamine-dependent behavior. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:7281-7288.